EMERGENT BIOSOLUTIONS INC. Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- EMERGENT BIOSOLUTIONS INC. payments for repurchase of common stock for the quarter ending 2026-06-30 was $9.00M, a 30.43% increase year-over-year.
- EMERGENT BIOSOLUTIONS INC. payments for repurchase of common stock for the quarter ending 2026-03-31 was $9.00M.
- EMERGENT BIOSOLUTIONS INC. payments for repurchase of common stock for the quarter ending 2025-12-31 was $9.10M.
- EMERGENT BIOSOLUTIONS INC. payments for repurchase of common stock for the quarter ending 2025-09-30 was $8.90M.
- EMERGENT BIOSOLUTIONS INC. payments for repurchase of common stock for fiscal 2025 was $24.90M.
- EMERGENT BIOSOLUTIONS INC. payments for repurchase of common stock for fiscal 2024 was $0.00.
- EMERGENT BIOSOLUTIONS INC. payments for repurchase of common stock for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- EMERGENT BIOSOLUTIONS INC. payments for repurchase of common stock for fiscal 2022 was $82.10M, a 22.55% decline from fiscal 2021.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2026-06-30 | $9.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $36.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $9.00M 10-Q · filed 2026-05-01 | $33.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $9.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $24.90M 10-K · filed 2026-02-27 |
| 2025-09-30 | $8.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $15.80M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $6.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $6.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-01 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $0.00 10-K · filed 2026-02-27 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $0.00 10-K · filed 2026-02-27 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-12-11 | $200.00K derived: sum of 4 quarters · filed 2025-03-04 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $200.00K derived: sum of 4 quarters · filed 2025-03-04 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-10 | $24.60M derived: sum of 4 quarters · filed 2025-03-04 |
| 2022-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $82.10M 10-K · filed 2025-03-04 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-12-11 | $187.90M derived: sum of 4 quarters · filed 2024-03-08 |
| 2022-06-30 | $24.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $187.90M derived: sum of 4 quarters · filed 2024-03-08 |
| 2022-03-31 | $57.50M 10-Q · filed 2023-05-10 | $163.50M derived: sum of 4 quarters · filed 2024-03-08 |
| 2021-12-31 | $106.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $106.00M 10-K · filed 2024-03-08 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | |
| 2021-03-31 | $0.00 10-Q · filed 2022-04-29 | |
| 2020-12-31 | $0.00 10-K/A · filed 2023-12-11 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $0.00 10-K · filed 2022-02-25 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $0.00 derived: sum of 4 quarters · filed 2021-02-19 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-02 | $0.00 derived: sum of 4 quarters · filed 2021-02-19 |
| 2019-03-31 | $0.00 10-Q · filed 2019-05-08 | $0.00 derived: sum of 4 quarters · filed 2021-02-19 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-19 | $100.00K 10-K · filed 2021-02-19 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $33.12M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-02 | $33.12M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-03-31 | $100.00K 10-Q · filed 2019-05-08 | $33.12M derived: sum of 4 quarters · filed 2020-02-25 |
| 2017-12-31 | $33.02M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $33.10M 10-K · filed 2020-02-25 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-02 | $83.00K derived: sum of 4 quarters · filed 2019-02-22 |
| 2017-06-30 | $2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $83.00K derived: sum of 4 quarters · filed 2019-02-22 |
| 2017-03-31 | $81.00K 10-Q · filed 2018-05-04 | $81.00K derived: sum of 4 quarters · filed 2019-02-22 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $0.00 10-K · filed 2019-02-22 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | |
| 2016-03-31 | $0.00 10-Q · filed 2017-05-05 | |
| 2015-12-31 | $100.00K 10-K · filed 2018-02-23 | |
| 2014-12-31 | $200.00K 10-K · filed 2017-02-28 | |
| 2013-12-31 | $213.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $213.00K 10-K · filed 2016-02-29 |
| 2012-12-31 | $4.45M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-09 | $5.91M 10-K · filed 2015-03-09 |
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-10 | $0.00 10-K · filed 2014-03-10 |
| 2010-12-31 | $0.00 10-K · filed 2013-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |